Neo Ivy Capital Management bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 83,966 shares of the biopharmaceutical company’s stock, valued at approximately $1,443,000. Halozyme Therapeutics accounts for approximately 0.8% of Neo Ivy Capital Management’s investment portfolio, making the stock its 17th largest holding. Neo Ivy Capital Management owned 0.06% of Halozyme Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in HALO. NumerixS Investment Technologies Inc increased its stake in shares of Halozyme Therapeutics by 70.7% during the second quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares during the period. Steward Partners Investment Advisory LLC bought a new position in Halozyme Therapeutics during the 2nd quarter worth $49,000. Quantamental Technologies LLC bought a new position in Halozyme Therapeutics during the 2nd quarter worth $173,000. CWM Advisors LLC bought a new position in Halozyme Therapeutics during the 2nd quarter worth $175,000. Finally, Shell Asset Management Co. bought a new position in Halozyme Therapeutics during the 1st quarter worth $229,000. Institutional investors own 82.58% of the company’s stock.
Halozyme Therapeutics stock traded up $0.08 during mid-day trading on Friday, reaching $16.37. 764,968 shares of the company were exchanged, compared to its average volume of 667,736. Halozyme Therapeutics, Inc. has a 12 month low of $13.24 and a 12 month high of $18.76. The company has a fifty day simple moving average of $16.32 and a 200-day simple moving average of $16.29. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 2.57. The firm has a market cap of $2.38 billion, a PE ratio of -29.23 and a beta of 1.81.
HALO has been the topic of a number of recent research reports. Zacks Investment Research upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating and set a $18.00 price objective on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald raised their price objective on Halozyme Therapeutics from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, July 1st. ValuEngine lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th. Barclays restated a “sell” rating and set a $17.00 price objective on shares of Halozyme Therapeutics in a research note on Monday, August 12th. Finally, BidaskClub upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $20.00.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Further Reading: What is Call Option Volume?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.